🚨BREAKING🚨 @FDA grants priority review to @TakedaPharma's zasocitinib drug for moderate-to-severe plaque psoriasis. See what the phase 3 data showed: hcplive.com/view/fda-priorit…

It's day 2 at #LEADderm 2026! We're still on the ground in Newport Beach, CA, talking leadership, innovation, and what it takes to lead in dermatology today.🔎 Follow along: hcplive.com/clinical/dermato…

Are you attending LEADderm on Aug 29th-30th?🗓️ Founded by #dermatology leader Jennifer Soung, MD, this 2-day meeting pairs derm clinical updates with mentorship, negotiation, and career growth. 🔗See what's on deck: hcplive.com/view/conference-…

Weight loss or direct anti-inflammatory effect? Dermatologists are still untangling how GLP-1 receptor agonists may be helping #psoriasis and #HS patients. 📽️Full video feature: hcplive.com/view/glp1s-derma…

June was a busy month in #dermatology. 📌 FDA approvals 📌 Conference coverage 📌 New psoriasis & atopic dermatitis data 📌 Podcast highlights See the 8 biggest stories you may have missed: hcplive.com/view/8-dermatolo…

The Revolutionizing Atopic Dermatitis (RAD) Conference 2026 is underway, and HCPLive is here!🤠 check out new expert interviews, clinical updates, emerging data, and key takeaways from one of the leading meetings in atopic dermatitis. #RAD2026 🔗View: hcplive.com/conference/revol…

🚨NEW🚨 The @FDA has included #bemotrizinol as a permitted active ingredient in its list of over-the-counter (OTC) sunscreen products. This marks the first addition of an active ingredient to the sunscreen monograph since the late 1990s.☀️ 🔗More here: hcplive.com/view/fda-adds-be…

🚨NEW🚨 A supplemental New Drug Application (sNDA) has been submitted by @ArcutisBio to the #FDA to broaden the indication of roflumilast cream 0.05% (Zoryve) for mild to moderate atopic dermatitis in infants down to 3 months of age. 🔗More: hcplive.com/view/roflumilast…

🚨NEW🚨 @US_FDA expands dupilumab (Dupixent) to children aged 2–11 with uncontrolled chronic spontaneous urticaria (CSU)—the first biologic approved for this population in the US. Read more: hcplive.com/view/fda-expands…

New on the #SkinofColorSavvy podcast 🎧... Dr. Vinod Nambudiri of @BrighamWomens, discusses the expanding AAD clinical image collection—addressing gaps in skin tone representation and improving diagnostic accuracy. 🔗 hcplive.com/view/skin-of-col… #Dermatology #AAD2026

March was anything but quiet in dermatology 👀 Head-to-head trial shakeups, long-term data, and FDA movement all made waves at #AAD2026. What could this mean for psoriasis & atopic dermatitis care? Read more: hcplive.com/view/6-dermatolo…

Day 2️⃣ of #AAD2026 coverage is LIVE! 🎙️ We're on the ground in Denver bringing you the latest interviews, data, and insights from the Annual Meeting. Stay tuned — more is coming all day. 👇 hcplive.com/conference/aad

🚨NEW🚨 The @US_FDA has approved icotrokinra for the treatment of psoriasis. The drug is specifically indicated for adults and pediatric patients aged 12 years and older weighing at least 40 kg who are candidates for systemic therapy or phototherapy. 🔗hcplive.com/view/icotrokinra…

🚨NEW🚨 Recent phase 3b findings released by @EliLillyandCo suggest combining ixekizumab (Taltz) + tirzepatide (Zepbound) improved skin clearance and weight loss more than ixekizumab alone in #psoriasis patients with obesity/overweight. More: hcplive.com/view/ixekizumab-…

RAD 2026 is calling for abstracts that highlight innovation and real-world insights in atopic dermatitis. Share your work with a community dedicated to advancing dermatologic care. 📩 Abstract submissions due May 1, 2026 🔗 Submit here: hubs.li/Q03-q2390

At #MauiDerm 2026, Linda Stein Gold, MD, discusses emerging psoriasis therapies—from high-efficacy nonsteroidal topicals to promising oral agents like icotrokinra targeting the IL-23 receptor. 🔗 hcplive.com/view/discussing-…

Have you caught up with the latest updates from #MauiDerm2026 (@MauiDerm)?🌴 💡We're on-site, covering the latest in #dermatology news and interviews with leaders in the field! 🔗Check out this page and stay tuned for updates later today: hcplive.com/conference/maui-…

🎙️A new on-site episode of #SkinofColorSavvy spotlights the @SkinOfColor's 'Meeting the Challenge Summit.' Leaders, clinicians, and trainees discuss advancing equity, inclusive trial design, & trust in #dermatology research. 🔗View: hcplive.com/view/skin-of-col…

2025 is coming to a close. We're celebrating with our 9th annual #ThisYearInMedicine series. Throughout December, we'll be spotlighting the trends, stories, and data that defined specialty care this past year Check back on this thread throughout the month for installments!

AI promises big things in dermatology—but what are the pitfalls? 🖥️ A new HCPLive deep-dive examines overreliance, training concerns & real-world challenges, with commentary from leading experts.🤔 🔗 View here: hcplive.com/view/ai-in-derma… #dermatology #AI